CLINICALLY IMPORTANT DETERIORATION AMONG PATIENTS WITH COPD TREATED WITH GLYCOPYRROLATE EFLOW CS OR TIOTROPIUM IN A LONG-TERM OPEN-LABEL STUDY

被引：0
|
作者：
Kerwin, Edward [1 ]
Murray, Lindsey [1 ]
Ganapathy, Vaidyanathan [1 ]
Dembek, Carole [1 ]
Rajagopalan, Krithika [1 ]
机构：
[1] Allergy & Asthma Ctr Southern Oregon, Medford, OR USA
来源：
CHEST | 2018年 / 154卷 / 04期
关键词：
D O I：
10.1016/j.chest.2018.08.700
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：777A / 778A
页数：2
相关论文
共 50 条
  • [1] Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Glycopyrrolate Eflow® Closed System (CS) (nebulized Glycopyrrolate) in Pooled Data from Two Randomized, Double Blind, Placebo-Controlled Studies
    Kerwin, E. M.
    Murray, L.
    Ganapathy, V.
    Dembek, C.
    Rajagopalan, K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [2] Long-term outcome following first clinically important deterioration in COPD
    Naya, Ian
    Tombs, Lee
    Mullerova, Hana
    Compton, Chris
    Jones, Paul
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [3] Long-term outcomes following first short-term clinically important deterioration in COPD
    Naya, Ian P.
    Tombs, Lee
    Muellerova, Hana
    Compton, Christopher
    Jones, Paul W.
    [J]. RESPIRATORY RESEARCH, 2018, 19
  • [4] Long-term outcomes following first short-term clinically important deterioration in COPD
    Ian P. Naya
    Lee Tombs
    Hana Muellerova
    Christopher Compton
    Paul W. Jones
    [J]. Respiratory Research, 19
  • [5] Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS
    Stephenson, Judith J.
    Dembek, Carole
    Caldwell-Tarr, Amanda
    Conto, Rebecca M.
    Paullin, Mark
    Kerwin, Edward M.
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 1713 - 1727
  • [6] Incidence of Chronic Obstructive Pulmonary Disease Symptom-Defined Exacerbations: Exploratory Analysis from a Long-Term Open-Label Active-Controlled Safety Trial of Nebulized Glycopyrrolate/eFlow® CS
    Kerwin, E. M.
    Ganapathy, V.
    Murray, L.
    Rajagopalan, K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [7] Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies
    Anzueto, Antonio R.
    Kostikas, Konstantinos
    Mezzi, Karen
    Fucile, Sebastian
    Bader, Giovanni
    Shen, Steven
    Banerji, Donald
    Fogel, Robert
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [8] Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
    Ford, Janet H.
    Stauffer, Virginia L.
    McAllister, Peter
    Akkala, Sreelatha
    Sexson, Matthew
    Ayer, David W.
    Wang, Shufang
    [J]. QUALITY OF LIFE RESEARCH, 2021, 30 (02) : 455 - 464
  • [9] Patient Functioning and Disability among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
    McAllister, Peter
    Ford, Janet H.
    Stauffer, Virginia L.
    Sexson, Matthew
    Ayer, David
    Wang, Shufang
    [J]. NEUROLOGY, 2020, 94 (15)
  • [10] Patient Functioning and Disability Among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
    McAllister, P.
    Ford, J.
    Stauffer, V
    Sexson, M.
    Ayer, D.
    Wang, S.
    [J]. HEADACHE, 2019, 59 : 99 - 100
12345